Found: 3
Select item for more details and to access through your institution.
Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 study.
- Published in:
- BMC Cancer, 2024, v. 24, n. 1, p. 1, doi. 10.1186/s12885-024-12153-5
- By:
- Publication type:
- Article
Factors Influencing Infusion-Related Reactions Following Dosing of Reference Rituximab and PF-05280586, a Rituximab Biosimilar.
- Published in:
- BioDrugs, 2021, v. 35, n. 4, p. 459, doi. 10.1007/s40259-021-00487-6
- By:
- Publication type:
- Article
A Randomized, Double-Blind, Efficacy and Safety Study of PF-05280586 (a Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera®) in Subjects with Previously Untreated CD20-Positive, Low-Tumor-Burden Follicular Lymphoma (LTB-FL).
- Published in:
- BioDrugs, 2020, v. 34, n. 2, p. 171, doi. 10.1007/s40259-019-00398-7
- By:
- Publication type:
- Article